Investor Alert: Seek advice from Kessler Topaz Meltzer & Check, LLP on RARE…
rug, setrusumab
Investor action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to the investor
If you purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, you may be affected by a securities fraud class action lawsuit. Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing allegations of material misstatements and omissions related to their drug, setrusumab. The lawsuit, filed in the United States District Court for the Northern District of California, allows investors until April 6, 2026, to file for lead plaintiff status and seek potential recovery options.
Throughout the Class Period, Ultragenyx Pharmaceutical Inc. is accused of misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta. The complaint alleges that Ultragenyx downplayed the risk that patients in their Phase III study would not achieve a significant reduction in annualized fracture rate (AFR), creating a false impression of reliable information. Investors were allegedly misled about the company’s optimism in the study’s results and interim analysis benchmarks as they were based on Phase II results without a placebo control group for adequate comparison. This oversight led to misleading statements about Ultragenyx’s business operations, and prospects.
Investors who held RARE common stock during the Class Period have the option to file for lead plaintiff status by April 6, 2026. They can contact Kessler Topaz Meltzer & Check, LLP for a complimentary case evaluation to explore their recovery options. By participating in the lead plaintiff process, investors will have the opportunity to potentially recover losses incurred due to the alleged securities fraud. Lead plaintiffs typically represent the class members in the litigation, directing legal proceedings on their behalf.
Ultragenyx investors are encouraged to be informed about the ongoing securities fraud lawsuit and consider their options to participate in the recovery process. Kessler Topaz Meltzer & Check, LLP, a prominent U.S. plaintiff-side law firm specializing in securities-fraud class actions, is available to guide and assist investors through the lead plaintiff process. Their experienced team can provide information and support to help investors seek potential recovery. For further details about the case and legal representation, visit the firm’s website for more information.
In conclusion, investors who have been impacted by the alleged securities fraud involving Ultragenyx Pharmaceutical Inc. are advised to take action and explore their options to seek recovery. By engaging with legal counsel and participating in the lead plaintiff process, affected investors can work towards potential remedies for losses incurred during the Class Period. It is essential for investors to stay informed about the developments in the lawsuit and consider their role in the recovery process to protect their rights and interests.